Translating Scientific Breakthroughs into Promise for Patients

From discovery through commercialization, all of us at Ardelyx are driven to advance targeted therapies where significant medical needs persist. We have developed a unique and innovative platform that has enabled the discovery of new biological mechanisms and pathways to create targeted, first-in-class, oral, small molecule therapies to meet these needs. Our lead candidate, tenapanor, is currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

With Integrity and Dedication, We Make a Difference for Patients

Join Us

We are… Passionate. Fearless. Dedicated. Inclusive!

Patients & Families

Translating scientific breakthroughs into promise for patients.

For Investors

Creating value from

Recent News

October 22, 2020

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and...

October 22, 2020

Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

October 12, 2020

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a...